Sartorius Valuation
Is 0NIQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0NIQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0NIQ (€172.88) is trading below our estimate of fair value (€227.38)
Significantly Below Fair Value: 0NIQ is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0NIQ?
Key metric: As 0NIQ is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0NIQ's PS Ratio? | |
|---|---|
| PS Ratio | 4.4x |
| Sales | €3.32b |
| Market Cap | €13.14b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.5x |
| Enterprise Value/EBITDA | 23.7x |
| PEG Ratio | 5.2x |
Price to Sales Ratio vs Peers
How does 0NIQ's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.5x | ||
ONT Oxford Nanopore Technologies | 7.1x | 22.6% | UK£1.2b |
ERGO Ergomed | 4.6x | 8.8% | UK£701.1m |
MXCT MaxCyte | 7.8x | 20.5% | UK£281.6m |
HVO hVIVO | 2.6x | 4.4% | UK£172.8m |
0NIQ Sartorius | 4.4x | 9.3% | €13.1b |
Price-To-Sales vs Peers: 0NIQ is good value based on its Price-To-Sales Ratio (4.4x) compared to the peer average (5.8x).
Price to Sales Ratio vs Industry
How does 0NIQ's PS Ratio compare vs other companies in the European Life Sciences Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 0NIQ is expensive based on its Price-To-Sales Ratio (4.4x) compared to the European Life Sciences industry average (4.3x).
Price to Sales Ratio vs Fair Ratio
What is 0NIQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4.4x |
| Fair PS Ratio | 4.8x |
Price-To-Sales vs Fair Ratio: 0NIQ is good value based on its Price-To-Sales Ratio (4.4x) compared to the estimated Fair Price-To-Sales Ratio (4.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Formycon
€820.2m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€46.50
7D
-3.8%
1Y
-26.2%
Dermapharm Holding
€1.9b
Manufactures and sells off-patent branded pharmaceutical products in Germany.
0A5J
€34.35
7D
7.7%
1Y
-14.5%
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€62.35
7D
-5.9%
1Y
20.0%